Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.69 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27972144 | 1.00 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL3444195 | 0.90 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3LTA4H | |
| SCHEMBL2267290 | 0.90 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3LTA4H | |
| SCHEMBL796789 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL9555741 | 0.88 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3TDP1LTA4H | |
| SCHEMBL27996160 | 0.88 | LTA4H (0.68) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL27722831 | 0.88 | LTA4H (0.68) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL27722812 | 0.88 | LTA4H (0.68) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL1475614 | 0.87 | TDP1 (0.70) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 | |
| SCHEMBL27722933 | 0.86 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| EP-2454234-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9227933-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227933-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9120746-B2 | Crystalline form of a 3-phenoxymethylpyrrolidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120746-B2 | Crystalline form of a 3-phenoxymethylpyrrolidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-07 | — | — | US | disclosed |
| CN-103038211-B | Crystalline forms of 3-phenoxymethylpyrrolidine compounds | THERAVANCE INC | 2015-04-15 | — | — | CN | disclosed |
| US-20150080450-A1 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2011008666-A2 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| EP-0736526-B1 | Pyrazolidine derivative, radical scavenger, brain-infarction depressant, and brain-edema depressant | SHISEIDO CO LTD (JP) | 2003-02-12 | — | — | EP | disclosed |
| EP-0561847-B1 | PHOTOSENSITIVE POLYMERS AND PRINTING PLATES | LASTRA SPA (IT) | 1997-08-27 | — | — | EP | disclosed |
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0561847-A1 | PHOTOSENSITIVE POLYMERS AND PRINTING PLATES. | LASTRA SPA (IT) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010523-A1 | PHOTOSENSITIVE POLYMERS AND PRINTING PLATES | LASTRA S.P.A. (IT) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885SLC6A3 6/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | SLC6A2 1380/4885SLC6A4 809/4885SLC6A3 993/4885 |
| US-20150080450-A1 | CRYSTALLINE FORM OF A 3-PHENOXYMETHYLPYRROLIDINE COMPOUND | REN, PKD1, PKD2 | SLC6A2 1355/4885SLC6A4 656/4885SLC6A3 590/4885 |
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | SLC6A2 1830/4885SLC6A4 1708/4885SLC6A3 3656/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | SLC6A2 2415/4885SLC6A4 2456/4885SLC6A3 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.